Based on the current results, we can confirm that XCL1/XCR1 and XCL1/ITGA9 signaling play important roles in CCI-induced neuropathy; however, ITGA9 seems to be a more potent neuronal target and may serve as an innovative strategy for the polypharmacotherapy of neuropathic pain in combination with opioids. The gene discussed is ITGA9; the disease is neuropathy.